Literature DB >> 12113323

Multiple doses of secretin in the treatment of autism: a controlled study.

E Sponheim1, G Oftedal, S B Helverschou.   

Abstract

UNLABELLED: Dramatic effects on autistic behaviour after repeated injections of the gastrointestinal hormone secretin have been referred in a number of case reports. In the absence of curative and effective treatments for this disabling condition, this information has created new hope among parents. Although controlled studies on the effect of mainly one single dose have not documented any effect, many children still continue to receive secretin. Six children enrolled in a double-blind, placebo-controlled crossover study in which each child was its own control. Human synthetic secretin, mean dose 3.4 clinical units, and placebo were administered intravenously in randomized order every 4th wk, on three occasions each. The measurement instruments were the visual analogue scale (VAS) and the aberrant behaviour checklist (ABC). Statistically significant differences were found for placebo in 3 out of 6 children and for secretin in one child, using parental ratings only (VAS scores). Differences were small and lacked clinical significance, which was in accordance with the overall impression of the parents and teachers and visual inspection of graphs.
CONCLUSION: In this placebo-controlled study, multiple doses of secretin did not produce any symptomatic improvement.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12113323     DOI: 10.1080/080352502753711669

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  6 in total

1.  In children with autism, is intravenous secretin more effective than placebo in improving social skills, communication, behaviour or global functioning?: Part A: Evidence-based answer and summary.

Authors:  Susan Petryk
Journal:  Paediatr Child Health       Date:  2004-04       Impact factor: 2.253

Review 2.  Gastrointestinal factors in autistic disorder: a critical review.

Authors:  Craig A Erickson; Kimberly A Stigler; Mark R Corkins; David J Posey; Joseph F Fitzgerald; Christopher J McDougle
Journal:  J Autism Dev Disord       Date:  2005-12

Review 3.  Intravenous secretin for autism spectrum disorders (ASD).

Authors:  Katrina Williams; John A Wray; Danielle M Wheeler
Journal:  Cochrane Database Syst Rev       Date:  2012-04-18

Review 4.  Secretin as a treatment for autism: a review of the evidence.

Authors:  Barbara E Esch; James E Carr
Journal:  J Autism Dev Disord       Date:  2004-10

5.  Baseline factors predicting placebo response to treatment in children and adolescents with autism spectrum disorders: a multisite randomized clinical trial.

Authors:  Bryan H King; Kimberly Dukes; Craig L Donnelly; Linmarie Sikich; James T McCracken; Lawrence Scahill; Eric Hollander; Joel D Bregman; Evdokia Anagnostou; Fay Robinson; Lisa Sullivan; Deborah Hirtz
Journal:  JAMA Pediatr       Date:  2013-11       Impact factor: 16.193

6.  Short report: Autistic gastrointestinal and eating symptoms treated with secretin: a subtype of autism.

Authors:  Stefano Pallanti; Stefano Lassi; Giampaolo La Malfa; Marco Campigli; Roberto Di Rubbo; Giulia Paolini; Valentina Cesarali
Journal:  Clin Pract Epidemiol Ment Health       Date:  2005-11-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.